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Abstract
Background: Contrary to intuition, use of lower strength nicotine e-liquids might not offer reduced health risk if
compensatory puffing behaviour occurs. Compensatory puffing (e.g. more frequent, longer puffs) or user behaviour
(increasing the wattage) can lead to higher temperatures at which glycerine and propylene glycol (solvents used
in e-liquids) undergo decomposition to carbonyl compounds, including the carcinogens formaldehyde and
acetaldehyde. This study aims to document puffing patterns and user behaviour associated with using high
and low strength nicotine e-liquid and associated toxicant/carcinogen exposure in experienced e-cigarette users
(known as vapers herein).
Methods/design: A counterbalanced repeated measures design. Participants: Non-tobacco smoking vapers; have
used an e-cigarette for ≥3 months; currently using nicotine strength e-liquid ≥12mg/mL and a second or third
generation device. Intervention: This study will measure puffing patterns in vapers whilst they use high and low
strength nicotine e-liquid under fixed and user-defined settings, each for a week. The 4 counterbalanced conditions
are: i) low strength (6mg/mL), fixed settings; ii) low strength user-defined settings; iii) high strength (18mg/mL)
fixed settings; iv) high strength user-defined settings. Biomarkers of exposure to toxicants and carcinogens will be
measured in urine. In the second phase of this study, toxicant yields will be measured in aerosol generated using
a smoking machine operated to replicate the puffing behaviours of each participant. Primary outcomes: i) Puffing
patterns (mean puff number, puff duration, inter-puff interval and mL of liquid consumed) and user behaviour
(changes to device settings: voltage and air-flow) associated with using high and low strength nicotine e-liquid.
ii) Toxicant/carcinogen exposure associated with the puffing patterns/device settings used by our participants.
Secondary outcomes: i) Subjective effects. ii) comparisons with toxicant exposure from tobacco smoke (using
documented evidence) and with recommended safety limits. Sample size: Twenty participants.
Discussion: The findings will have important implications for public health messaging regarding the relative risks
and subjective effects associated with using high and low strength nicotine e-liquid, and for policy makers
regarding regulations on nicotine concentrations in e-liquids.
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Background
Electronic cigarette (known as e-cigarettes, ENDS and e-
cigs) use is becoming increasingly popular among
smokers wishing to quit or reduce smoking [1]. The rise
in popularity may in part be driven by consumer de-
mand for a less harmful alternative to smoking tobacco
and/or a desire to reduce nicotine intake. Indeed, the
often flavoured e-liquid offers a range of nicotine
strengths from 0 % to 2.0 % = 20 mg/mL (since the im-
plementation of the EU Tobacco Products Directive),
thus providing a new way for users to monitor and re-
duce their nicotine intake in a less ambiguous manner
than traditional cigarettes.
Smokers and vapers may opt for, or switch to, lower
nicotine strength e-liquid for a variety of reasons: the be-
lief that it is healthier; desire to wean off nicotine; or
due to the EU Tobacco Products Directive which stipu-
lates an upper limit of 20mg/mL nicotine concentrations
in e-liquids introduced in May 2016. However, contrary
to intuition, use of lower strength nicotine e-liquids
might not offer reduced health risk if compensatory
puffing behaviour occurs.
Compensatory puffing behaviour is well documented in
tobacco smokers. Smokers increase puff frequency, dur-
ation and volume when switching to a lower nicotine yield
cigarette [2–4] whilst maintaining high blood nicotine
levels [5, 6]. Exposure to tar in smoke known to contain
carcinogenic compounds is consequently increased [2, 7].
Compared with vapers, smokers typically take shorter
puffs [8] and after switching to vaping, can adjust their
puffing patterns within a week [8, 9]. Two small scale
laboratory studies suggest that vapers can also compensate
for lower nicotine strength e-liquid by altering their
puffing patterns. Ramôa and colleagues [10], using a ten-
puff protocol, reported that vapers took larger and deeper
puffs with 0mg/mL vs. 36mg/mL nicotine strength e-
liquid, which the authors concluded may reflect an
attempt to self-titrate due to the absence of nicotine.
Similarly, we Dawkins et al. [11] observed compensatory
puffing patterns in which vapers took longer, more fre-
quent puffs, and doubled the amount of e-liquid
consumed during a one-hour ad lib puffing period with a
low (6mg/mL) compared with a high (24mg/mL) strength
nicotine e-liquid. In this study the device settings (voltage,
wattage, resistance of the coil and air-flow) were fixed
reflecting standard second-generation devices. In reality,
experienced users may adjust these parameters when
using lower nicotine strength e-liquid and this may in
turn, influence toxicant/carcinogen exposure. In the user-
defined condition proposed here, we will allow users to
adjust the voltage and air-flow of the device (although
atomiser resistance will be kept constant).
Exposure to toxicants and carcinogens from e-cigarettes
is 9–450 times lower than from tobacco cigarettes [12],
however, vaping is not risk-free and toxicant exposure will
be related to the amount of e-liquid consumed. Longer,
more frequent puffs and higher power may also lead to
higher temperatures at which glycerine and propylene
glycol, (solvents used in e-liquids), undergo decomposition
to carbonyl compounds including the carcinogens formal-
dehyde and acetaldehyde [13]. If compensatory puffing
patterns and changes to device settings lead to increased
toxicant/carcinogen exposure due either to increased liquid
consumption, increased temperature or both, switching to
lower strength nicotine e-liquid may therefore not be the
lower risk option.
We will measure puffing patterns in vapers in natural-
istic conditions over four weeks whilst they use high and
low strength nicotine e-liquid under fixed and user-
defined (changes to device such as power output and
air-flow allowed) settings, each for a week (4 conditions).
Toxicant and carcinogen exposure will be assessed by
measuring i) biomarkers of exposure in urine samples
collected from participants and ii) yields of toxicants in
e-cigarette aerosol generated for each individual under
identical puffing conditions in the lab. Capturing e-
cigarette puffing patterns and behaviour will not only
inform the parameters of toxicity of the product used in
the study but will have wider applicability for other
researchers exploring toxicants/carcinogens in aerosol
by ensuring realistic puffing patterns are used. Indeed, al-
though the effects of solvent and power level on toxicant/
carcinogen exposure have been explored [13, 14], labora-
tory studies to date have tested all products using the same
puffing regime (ranging between studies from 1.8 to 4 s
puff duration with a 10 to 60s inter-puff interval [IPI];
[13–17]. Such standardised puffing regimes not only fails
to capture potential puffing variation between devices [18]
and individuals [19, 20], but does not account for compen-
satory puffing with different nicotine yields [10, 11].
Whilst puffing patterns differed across high and low nico-
tine strength e-liquid conditions in our previous study,
nicotine craving and withdrawal symptoms did not differ
[11] suggesting that compensatory puffing behaviour was
effective at least in the short term under laboratory condi-
tions. Nevertheless, there was considerable individual vari-
ation on subjective reporting and laboratory conditions
may not produce reliable evidence with respect to subject-
ive effects because these settings can elicit unrealistic puff-
ing behaviour [21]. The study outlined here will use a larger
sample under naturalistic conditions to determine if and
how real life puffing patterns associated with the use of
high and low strength nicotine e-liquids differentially affect
withdrawal symptoms, satisfaction and nicotine intake.
Understanding the risks of compensatory puffing will have
important implications for public health messaging regard-
ing the relative risks and subjective effects associated with
using high and low strength nicotine e-liquid, and for policy
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makers regarding regulations on nicotine concentrations in
e-liquids.
Objectives
This Cancer Research UK (CRUK) funded project will
investigate e-cigarette puffing patterns and user behav-
iour associated with high and low strength nicotine e-
liquids and how this affects toxicant and carcinogen
exposure. We aim to measure natural consumer puffing
behaviour in phase one of the experiment and to repli-
cate these patterns within a laboratory setting within
phase two. Specifically, we present four objectives:
 To measure puffing patterns (mean number of
puffs, mean puff duration, mean IPI and mL liquid
consumed) and user behaviour-changes to device
settings - voltage and air-flow where permitted-
associated with using high and low strength nico-
tine e-liquid to ascertain if and how compensatory
puffing behaviour occurs.
 To explore if and how puffing patterns/user
behaviour associated with high and low strength
nicotine e-liquids affect satisfaction, craving,
withdrawal symptoms and nicotine intake as
measured by cotinine level in saliva.
 To determine whether puffing patterns/user
behaviours associated with using low vs. high
strength nicotine e-liquid increases toxicant/carcinogen
exposure as measured by i) biomarker levels in users’
urine and ii) toxicant yields in e-cigarette aerosol
(as measured in a laboratory setting).
 To assess the risk of whether toxicant/carcinogen
exposure levels associated with the puffing patterns/
device settings used by our participants are at a level
likely to affect human health by comparing these
with those found in tobacco smoke and against
recommended safety limits.
Study design
A repeated measured, counterbalanced, prospective co-
hort study.
Methods
Study setting
Figure 1 presents the study phases and stages.
Phase one
This study seeks to measure and replicate real-life puff-
ing behaviours. Participants will receive minimal inter-
vention in phase one of the study, only meeting with the
research team on five occasions at baseline and at the
end of each condition. Puffing data will be recorded by
the e-cigarette device as participants complete their daily
routines for the duration of phase one.
Puffing, biochemical and questionnaire data will be
collected at London South Bank University within the
School of Applied Sciences Psychology laboratories.
Urine and saliva samples will be sent off campus (see
details below in Data collection) for analysis.
Phase two
Will replicate individual puffing topography from phase
one, also at an external laboratory (see details below, in
Data collection).
Eligibility criteria
Participants will be eligible to take part providing they
are aged 18 or over, an ex-smoker (reporting having not
smoked at all for at least 3 months, confirmed with a
carbon monoxide reading in exhaled breath of < 10ppm)
and a current, exclusive daily vaper, reporting e-cigarette
use for ≥3 months. We have stipulated that current
vapers should be using a nicotine strength e-liquid
≥12mg/mL (1.2 %) with a second or third generation
device (open-systems with re-fillable tanks). Participants
Fig. 1 Illustration of Phase one and Phase two and respective stages
Cox et al. BMC Public Health  (2016) 16:999 Page 3 of 9
would be excluded from taking part if they report any of
the following: Under 18 years of age; pregnant or lactat-
ing female; current tobacco smoking or a CO reading >
10ppm; marijuana or illicit drug use; are unable to
provide written informed consent; or report any serious
medical condition (including unstable angina, chronic
obstructive pulmonary disease, cancer).
Interventions
Table 1 illustrates participant interventions at all stages
of the study.
There are two phases to this study. Phase one will meas-
ure puffing patterns in vapers over four weeks whilst they
use high and low strength nicotine e-liquid under fixed
and user-defined (changes to device allowed) settings, each
for a week. The 4 conditions are: i) low strength (6mg/
mL), fixed settings; ii) low strength user-defined settings;
iii) high strength (18mg/mL) fixed settings; iv) high
strength user-defined settings). Biomarkers of exposure will
be measured at the end of each trial, in urine and saliva,
for acrolein exposure (3-HPMA) and nicotine adsorption
(cotinine) respectively. Phase two of this study will analyse
e-cigarette aerosol (generated under average puffing
regimes for each participant) in a laboratory setting.
Participants will be contacted upon expressing interest
in taking part in the study, at this stage, the study details
will be provided and the inclusion/exclusion criteria will
be assessed. Upon agreeing to take part, participants will
receive further details about the study, a consent form to
complete and a date to attend the University for their
baseline assessment.
At the baseline visit, the researcher will explain the
study in further detail and read through the information
sheet with the participant ensuring that s/he fully under-
stands the requirements. Time will be allocated to answer
any further questions before written informed consent is
gained. Participants will then provide: a breath CO sample
to ensure non-smoking status; a saliva and urine sample;
and subjective ratings of nicotine craving and withdrawal
symptoms. They will then be provided with a third gener-
ation device (eVic Supreme), nautilus tank and e-liquid
(either 6mg/mL or 18mg/mL) to use for the next week
and given the opportunity to practice using the device.
Participants will also have the choice of one of four
flavours of e-liquid to choose from, based on one popular
flavour from different flavour categories (fruit, bakery,
menthol, tobacco). Participants can sample the flavours at
this initial meeting but are required to use the same
e-liquid throughout the 4 week period.
Table 1 Provides a summary of participant and data collection timeline
Study period
Enrolment Allocation Post-allocation Close-out
Timepoint -t1 0 t0 t1 t2 t3 t4 tx
Enrolment:
Eligibility screen X
Informed consent X
Allocation X
Intervention:
Fixed-user setting (6mg/mL nicotine or 18mg/mL) X X
Fixed-user setting (6mg/mL nicotine or 18mg/mL) X X
Assessments:
Demographics (e.g. age, gender, ethnic group, educational qualification) X X
Vaping and previous smoking history X X
Breath carbon monoxide (CO) sample X X X X X
Puffing behaviour and participant reports X X X X
Mood and Physical Symptoms Scale (MPSS) to record withdrawal symptoms X X X X X
Urge to vape X X X X X
Saliva sample X X X X X
Urine sample X X X X X
Adverse events X X X X X
Participant feedback X
Debrief X
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Over the course of the 4 weeks, the e-cigarette will
record puff number, puff duration, voltage, wattage and
resistance. The device does not record puff velocity or
volume, although these do not influence nicotine yield
[20, 22]. Participants will be asked to refrain from using
any other e-cigarette device, e-liquid or nicotine-
containing products. We acknowledge that compliance
may be an issue and will rely on participant’s self-reports
regarding non-compliance, deleting data from non-
compliant days. Participants will return to the University
after one week to collect the next batch of e-liquid and
to provide subjective ratings, breath CO, saliva and urine
samples. The researcher will download puffing and
device setting information from the device and the tank
will be thoroughly cleaned and the atomiser replaced,
participants will be asked to report on how much e-
liquid they have consumed over the week. This proced-
ure will be repeated on three further occasions in order
to capture information on puffing patterns subjective
effects ratings and nicotine intake and toxicants in urine
under each of four conditions.
All participants will start on fixed device settings (to
allow familiarisation with the device before allowing
participants to change setting), but we aim to counterbal-
ance the nicotine condition by half of the participants
starting on high strength 18mg/mL and half on low
strength 6mg/mL. At the beginning of week two, partici-
pants will continue to use the device under fixed-settings
but will be given a different strength of nicotine e-liquid
(dependent on which they received in week 1). We may, if
necessary, offer participants a week’s break from the study
during which time they can use their own device. If
participant compliance and retention is an issue, we may
recruit new participants for the second stage of phase one.
In weeks 3 and 4, the counterbalancing of weeks 1 & 2
will be repeated under user-defined settings.
Primary outcomes
Phase one
To document real-life puffing patterns (mean puff
number, puff duration, IPI and mL of e-liquid con-
sumed) and user behaviour (voltage, air-flow) associated
with using high (18mg/mL) and low strength (6mg/mL)
nicotine e-liquid illustrating if and how compensatory
puffing behaviour occurs.
Phase two
To record toxicant/carcinogen emissions associated with
puffing patterns/user behaviours associated with using
low vs. high strength nicotine e-liquid as measured by
biomarker levels in users’ urine and toxicant yields in
e-cigarette aerosol.
Secondary outcomes
Phase one
Subjective ratings of satisfaction, craving, withdrawal symp-
toms as well as nicotine intake (measured with cotinine
and calculated via mL of e-liquid consumed) under the four
conditions.
Phase two
A comparison of toxicant/carcinogen exposure levels
associated with the puffing patterns/device settings used
by our participants with those found in tobacco smoke
and against recommended safety limits using existing
published material.
Participant timeline
Table 1 presents the participant timeline and associated
interventions at each phase.
Sample Size
Twenty regular vapers will be recruited. The proposed
sample size is based on puff number and puff duration
results from Dawkins et al., ([11]: 2016) [7 :N = 22;]. We
observed effect sizes of d = 0.74 and d = 1.09 respectively.
A sample of N= 14 for puff number and N= 11 for puff
duration would allow us to detect effects at p < 0.10 with
90 % power.
Recruitment
An advert will be placed on London South Bank
University’s research participation scheme website, as well
as advertisement in e-cigarette café’s and on e-cigarette
forums as well as via twitter and direct e-mail to known
vapers.
Data collection
Phase one
Demographic information and vaping and previous
smoking history will be collected via questionnaire at
baseline assessment only.
At each session we will measure subjective craving
(‘urge to vape’), and withdrawal symptoms through
the use of the Mood and Physical Symptoms Scale
[23] Direct (e.g. hit, satisfaction) and Adverse (head-
ache, nausea) effects relating to nicotine/e-cigarette
use will be measured as previously described in
[19]. All questionnaires will be presented in paper
format. No permission is required to use any of
these scales.
E-cigarette puffing patterns and user behaviour will be
recorded by retrieving information on puff number, puff
duration, voltage, wattage and resistance recorded by a
third generation electronic cigarette provided to partici-
pants at the baseline assessment. Air flow settings are
not recorded and we rely on participant self-report for
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this information. Data will be downloaded from the
participants’ device and screened using myVapors software.
At all assessment phases we will measure exhaled car-
bon monoxide using the Bedfont Micro Smokerlyzer to
ensure non-smoking status. Participants producing read-
ings above 10ppm will be excluded from the analysis.
Saliva and urine samples will be taken from each
participant at every study visit (5 per participant). These
will be posted to ABS laboratories within 48 h of collec-
tion where they will be frozen at −20°C and stored until
the end of the study. Saliva will be assayed for cotinine
to determine nicotine intake and 3-hydroxy cotinine to
determine CYP 2A6 levels (rate of nicotine metabolism).
This will allow us to determine how successful compen-
satory puffing behaviour has been, controlling for nico-
tine metabolism rate if necessary. Urine will be assayed
for 3-HPMA to show acrolein exposure. If the develop-
ment of an LC-MS/MS method for estimation of formal-
dehyde exposure that is being performed to support
another study is successful, the urine samples will also
be assayed for formaldehyde exposure.
Phase two
In order to explore toxicant and carcinogen emission as-
sociated with these puffing patterns, at the second phase
of the study puffing and device setting information
collected from the participants will be used to create
average puffing regimes for each person. This phase of
the study will involve no human participants.
Within this second phase we will use the same e-
cigarette device and e-Liquids as phase 1. Aerosol will be
generated using the automatic smoking simulator, Palacz-
bot (previously used in several published studies; [24–27]),
a single, linear unit that allows the generation of e-cigarette
aerosols under specific conditions allowing us to mimic the
puffing behaviours of each participant in each condition.
Carbonyl compounds will be quantified using AT 1200
liquid chromatograph (Agilent Technologies: as described
below) and nicotine using Gas chromatography method
with Thermionic Specific Detector (GC-TSD, Varian Inc.)
Aerosol will be generated 3 (or 6 if necessary) times
for each analysis (for nicotine or carbonyl compounds)
to replicate each participant’s puffing patterns using the
same e-cigarette device setting under each of the four
conditions in phase 1. Aerosol will be tested for formal-
dehyde, acetaldehyde, acrolein, benzaldehyde and nico-
tine emission with puffing regimes.
Carbonyl compounds (12 compounds): The method of
aldehydes and ketones determination involves an adsorp-
tion of aldehydes and ketones aerosol mixture on a pipe
filled with silica gel saturated with 2,4-dinitrophenylhydra-
zine, desorption of the compounds with acetonitrile in
ultrasound washer, and determination using reverse phase
technique of high performance liquid chromatography on
AT 1200 liquid chromatograph (Agilent Technologies)
equipped with Zorbax Eclipse PAH column (4,6 x 250
mm, 5μm) and spectrophotometric detector DAD. This
allows determination of the following compounds: for-
maldehyde, acetaldehyde, acrolein, acetone, propionic
aldehyde, crotonaldehyde, butanal, benzaldehyde, isova-
leric aldehyde, valeric aldehyde, m-methylbenzaldehyde,
o-methylbenzaldehyde, p-methylbenzaldehyde, hexanal,
2,5-dimethylbenzaldehyde [10].
Nicotine will be analysed using gas chromatography
with Thermionic Specific Detector (GC-TSD, Varian
Inc.). CP-Sil 8CB, 25 m × 0.25 mm × 0.39 mm (1.2 mm;
Varian Inc.) capillary column with flow rate of helium of
2.4 ml/min will be used. Temperature of injector and
detector will be 300 °C, column temperature will be
increased from 60 to 200 °C (20 °C/min) and will be held
for 5 min. Injection volume will be 1microlitre, and
quinoline will be used as an internal standard.
Statistical methods
For each participant in each of the four conditions,
mean puff duration, puff number, and (for the user-
defined conditions) wattage, voltage and air-flow for
each day will be calculated and averaged across the
seven days (or reduced for the number of compliant
days if necessary) for that participant and condition.
Repeated measures Analysis of Variance (ANOVA) will
be used to compare puff duration, puff number, wattage,
voltage, cotinine and acrolein across relevant conditions.
We will also present mean and standard deviations for
carbonyl compounds and nicotine and use ANOVA to
explore any effects of condition on these variables.
We will estimate health risks by comparing levels of
toxicant and carcinogen exposure to a) tobacco smoking
(documented in the literature) and b) the Health and
Safety Executive (HSE) workplace exposure limits [28] in
order to provide useful information for public health
professionals and policy makers about the relative harms
associated with this level of exposure.
For each toxicant/carcinogen analysed, we will calculate
a new exposure index (e-cigarette exposure index, EEI),
i.e. total doses inhaled by individuals from e-cigarettes
over one day. The EEI for each toxicant will be calculated
by comparing doses inhaled from e-cigarette to doses that
would be inhaled from air with toxicant concentration
specified by the HSE long-term exposure limits. We will
assume an average lung ventilation rate and take into
account number of puffs taken per day. The EEI index
may be useful to compare relative risk of inhaling
toxicants from e-cigarettes. EEIs higher than 1.0 would
indicate that mean exposures from e-cigarettes exceed
exposure defined by HSE standards. We will verify if there
is a correlation between the calculated EEI generated from
the aerosol analysis with 3-HMPA concentration and
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(if assay is successful) formaldehyde estimated in urine.
The higher EEI, the higher health risk for users associated
with inhaling specific toxicants.
Ethical considerations
Ethical approval was granted by London South Bank
University (Application reference: UREC 1604) and has
been funded by Cancer Research UK (Application refer-
ence: C50878/A21130). Informed consent will be collected
in writing at the baseline session at the University prior to
any data collection. Participants will have already received
the information sheet and consent form via e-mail and
had a chance to discuss any aspect of the study via e-mail
or over the telephone with the researcher.
No sensitive data will be transferred electronically; it
will also be anonymised beforehand (i.e. numerical codes
will be used rather than names).
Discussion
The aim of this research is to investigate real-life e-cigarette
puffing patterns and user behaviour associated with high
and low strength nicotine e-liquids and how this affects
toxicant and carcinogen exposure.
There are notable factors which will challenge the process
of gaining the necessary evidence. The first relates to
recruitment and retention. We are seeking experienced
vapers with >3 months experience; we may expect vapers
with such experience to be attached to their current
devices, settings and e-liquid strengths and flavours and
therefore not forthcoming in sampling new products and e-
liquids. In order to mitigate this we have budgeted for wide
advertisement of the study and allowed 7 months for
recruitment and complete testing of 20 participants. Fur-
thermore, we wish to measure long-term puffing patterns
(over 4 weeks) beyond the timescale of previous research
[8, 11, 29, 30]. For the same reasons highlighted above,
participants may not be fully compliant, and may quit
during our trial or (especially during the low nicotine
strength weeks) compensate with their own devices or with
cigarette smoking. We seek to overcome this by a) discuss-
ing flavour requirements and offering a range of e-liquid
flavours, b) encouraging contact with the research team
throughout the study c) emphasising honest reporting
about non-compliance/use of other nicotine-containing
products and d) recruiting exclusive vapers (non dual-
users) who haven’t smoked for at least 3 months. A seven
day testing period under each condition means that we can
exclude data from non-compliant days without it having a
significant impact on our primary outcome, puffing
patterns (puff number, duration, IPI and mL e-liquid
consumed), which is essential for phase two. 3-HMPA (for
acrolein exposure) and cotinine, with a half-life of 72 h and
averaging 17 h respectively, [31, 32] may be more suscep-
tible to the use of other nicotine-containing products
(especially to occasional tobacco cigarette smoking) but will
we still be able to measure these in aerosol in phase two if
non-compliance proves to be an issue. Finally, non-
compliance itself is an interesting outcome and will still
allow us to conduct meaningful analysis of toxicant/car-
cinogen exposure associated with different puffing regimes.
As in our laboratory study [11], we will use inbuilt
e-cigarette software to capture information on puffing
patterns, a straightforward and arguably, more ecologically
valid procedure than CReSS pocket devices. This will
provide us with detailed information on each puff (time of
puff, length of puff), the IPI and overall number of puffs
allowing us to exclude data from non-compliant days and
to conduct more fine-grained analysis on the nature of
puffing patterns (timings, cycles and episodes of puffs over
24 h periods) if necessary. However, the device does not
record puff velocity or volume, although as noted earlier
these parameters do not appear to influence nicotine yield
[20, 22]. In the user-defined conditions, we will allow
users to adjust the voltage (recorded for each puff by the
device) and air-flow. The latter is not captured by the in-
built software and we will therefore have to rely on partici-
pant self-report (average for the day) for this information.
Experienced users may also be accustomed to adjusting
the resistance of the atomiser/coil when switching to a
lower nicotine strength e-liquid. We will request that
participants do not change the atomiser on the device but
if they do, the inbuilt software will record this information.
Although our study will not provide a definitive
answer to the safety of e-cigarette use under all circum-
stances, it will help to inform public health messaging
and policy making regarding the ‘safest’ way to vape and
the regulation of nicotine e-liquid strengths. If compen-
satory puffing patterns associated with using lower nico-
tine strength e-liquids result in higher toxicant exposure,
the use of higher nicotine strength e-liquids may be rec-
ommended. The findings will also provide the founda-
tions for future studies exploring the effects of a broader
range of e-cigarette devices, settings, nicotine strengths
and flavourings on puffing patterns and help to inform
the parameters of future aerosol toxicology studies.
The data collected are intended to benefit the general
public; we will therefore preserve all data resulting from
the study (with the exception of personal data) and make
it publically available with as few restrictions as possible.
We will disseminate a lay summary for participants,
explaining our findings and their importance. Once the
data has been finalized, it will be deposited in London
South Bank University’s open data repository. The find-
ings will be disseminated via open access peer-review
publication, conference presentations and press releases,
and shared with a number of charities, practitioners and
public health and policy organisations via presentations,
briefing papers and web-based material.
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